Neurocrine Closer To Ingrezza Label Expansion With Huntington’s Chorea Phase III Win

 
• By Joseph Haas
  
Brain research
Neurocrine thinks Ingrezza can better the competition in Huntington's chorea
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D